Telitacicept
Protein / enzyme therapeutic
Evidence outlook
Approved: Adults with IgA nephropathy (conditional approval) (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Latest reported trial: NCT05737160 · Phase 3 · met primary endpoint · grade pending
Also in development:Rheumatoid Arthritis · Phase 3 · investigational in the USSjögren's Disease · Phase 3 · investigational in the US · under NMPA reviewIgA Nephropathy · Phase 3 · investigational in the US
Also approved (5)
- Adults with IgA nephropathy (conditional approval)
- Adults with Sjögren's disease
- Adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis, in combination with conventional therapies
- Rheumatoid arthritis
- Systemic lupus erythematosus (conditional approval; later converted to full approval)
Development in Systemic Lupus Erythematosus stopped (2025-01) as a strategic decision by the sponsor. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05737160 NCT05737160 · Generalized Myasthenia Gravis This randomized, double-blind, placebo-controlled Phase 3 trial in China enrolled 114 adults with generalized myasthenia gravis, 57 per group, for 24 weeks of blinded treatment. The registered primary endpoint was the change in the MG-ADL score at Week 24. The score fell by 5.74 points with telitacicept against 0.91 with placebo, and the sponsor describes the improvement as significant, but it publishes no p-value or confidence interval. Registry results are not posted; the figures come from the sponsor's press release. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05737160 | 3 | Change from baseline in MG-ADL (Week 24) 2024-11-26 | Change in MG-ADL from baseline at Week 24: -5.74 with telitacicept 240 mg vs -0.91 with placebo (57 per group); 98.1% vs 12.0% had a reduction of 3 points or more. The release states the improvement was significant but gives no p-value or CI (RemeGen release, AAN 2025). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other BAFF / APRIL drugs
Povetacicept, aritinercept. Compare all 3 BAFF / APRIL drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Generalized Myasthenia Gravis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Telitacicept: this drug | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| Eculizumab (Soliris) | Approved | Monoclonal antibody | Complement C5 | Partial signal | NCT01997229: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) missed | |
| Efgartigimod Alfa (Vyvgart) | Approved | Antibody fragment | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo) | Approved | Antibody fragment | FcRn | not yet graded | No reviewed efficacy summary in this indication | |
| Inebilizumab | Approved | Monoclonal antibody | CD19 | Reliable signal | NCT04524273: Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population (Baseline and Week 26): Overall: Placebo -2.2 Score on a scale (95% CI -3 to -1.5) | Overall: Inebilizumab 300 mg -4.2 Score on a scale (95% CI -4.9 to -3.4) | |
| Ravulizumab (Ultomiris) | Approved | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Cemdisiran | Phase 3 | RNA / oligonucleotide | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Gefurulimab (Klygefa) | Phase 3 | Antibody-derived scaffold | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Iptacopan (Fabhalta) | Phase 3 | Small molecule | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication | |
| Pozelimab (Veopoz) | Phase 3 | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| Aritinercept | Phase 1/2 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(19 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Telitacicept to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (4)
December 2026 (4)
What to watch
What to watch
What to watch
What to watch
2027 (11)
January 2027 (2)
March 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (3)
What to watch
What to watch
What to watch
August 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (3)
July 2028 (1)
What to watch
2029 (1)
May 2029 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent